Verisante, Clarion Medical Technologies enter distribution agreement
Cancer detection technology developer Verisante has entered into an exclusive agreement with Clarion Medical Technologies to distribute the company's Verisante Aura optical system for skin lesion evaluation in Canada.
Cancer detection technology developer Verisante (Vancouver, BC, Canada) has entered into an exclusive agreement with Clarion Medical Technologies to distribute the company's Verisante Aura optical system for skin lesion evaluation in Canada. The distribution adds to Clarion's existing product line that relates to UV damage and skin care treatments, as well as dermatological products and devices utilizing optical technologies for various medical applications.
Verisante Aura is a noninvasive optical system that uses Raman spectroscopy to biochemically analyze the skin quickly, evaluating skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma, and basal cell carcinoma when a medical professional chooses to obtain additional information before making a final decision to biopsy. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals noninvasively.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Follow OptoIQ on your iPhone; download the free app here.
Subscribe now to BioOptics World magazine; it's free!